Medicine - Cardiology

Search results

• Bristol Myers Squibb continues to underperform Novartis India by 21.5% in the past month

  Fuster, V.

  27/05/25

  6 items of Media coverage

  Press/Media

• What’s the Damage With Long COVID? Advanced Imaging Reveals Clues

  Trivieri, M.

  27/05/25

  1 item of Media coverage

  Press/Media

• Present and future of Spanish cardiology meet this week at the Fundación Jiménez Díaz

  Fuster, V.

  26/05/25

  2 items of Media coverage

  Press/Media

• Researchers from Department of Cardiology Detail Findings in Art Therapy (Difference In Strategy and Clinical Outcomes of Left Main Disease In Japan and Non-japanese Countries Insight From Define-lm Registry)

  Kawase,, Y.

  26/05/25

  1 item of Media coverage

  Press/Media

• Weekly: Tourmaline Bio (TRML: $15.32) slides 7.5%, 2 weeks' volume in a week; -$1.24 [7.5%] Vol Index 1.8 [1 is avg]

  Fuster, V. & Bhatt, D. L.

  24/05/25

  1 item of Media coverage

  Press/Media

• Weekly: Orchestra BioMed Holdings (OBIO: $2.72) shares post worst week in seven weeks; -18c [6.2%]

  Reddy, V. Y.

  24/05/25

  1 item of Media coverage

  Press/Media

• Two-bagger Corcept Therapeutics (CORT: $78.69) climbs 4.8%; +$3.61 [4.8%]

  Fuster, V. & Bhatt, D. L.

  24/05/25

  1 item of Media coverage

  Press/Media

• How Bristol Myers Squibb's dividend compares to Its Peers

  Fuster, V.

  23/05/25

  2 items of Media coverage

  Press/Media

• How Bristol Myers Squibb's Tax Rate compares to Its Peers

  Fuster, V.

  22/05/25

  10 items of Media coverage

  Press/Media

• How Bristol Myers Squibb's dividend compares to Novartis India

  Fuster, V.

  21/05/25

  8 items of Media coverage

  Press/Media

• Doctors Address the Biggest Heart Health Concerns For Women Over 50

  Rozanski, A. R.

  21/05/25

  29 items of Media coverage

  Press/Media

• 26 Aussie Scientists Join Best Of Best

  Adams, D.

  21/05/25

  1 item of Media coverage

  Press/Media

• Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial Evaluating Pacibekitug in Patients with Elevated High-Sensitivity C-reactive Protein and Chronic Kidney Disease

  Fuster, V. & Bhatt, D. L.

  21/05/25

  1 item of Media coverage

  Press/Media

• Mount Sinai Surgeons Perform First Heart-Liver-Kidney Transplants in New York State

  Moss, N., Florman, S. & Anyanwu, , A.

  21/05/25

  1 item of Media coverage

  Press/Media

• Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial Evaluating Pacibekitug in Patients with Elevated High Sensitivity C reactive Protein and Chronic Kidney Disease

  Fuster, V. & Bhatt, D. L.

  20/05/25 → 21/05/25

  3 items of Media coverage

  Press/Media

• Mount Sinai Surgeons Perform First Heart-Liver-Kidney Transplants in New York State

  Moss, N., Florman, S. & Anyanwu, , A.

  21/05/25

  1 item of Media coverage

  Press/Media

• HMN 2025: How Surgeons carry out first heart-liver-kidney transplants in New York State

  Moss, N., Florman, S. & Anyanwu, , A.

  21/05/25

  1 item of Media coverage

  Press/Media

• Findings from Icahn School of Medicine at Mount Sinai Update Understanding of Atherectomy [Orbital Atherectomy Versus Balloon Angioplasty Before Drug-eluting Stent Implantation In Severely Calcified Lesions Eligible for Both Treatment Strategies ...]

  Ali, Z.

  20/05/25

  1 item of Media coverage

  Press/Media

• Tourmaline Bio to Presented Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025

  Fuster, V. & Bhatt, D. L.

  20/05/25

  1 item of Media coverage

  Press/Media

• Bristol Myers Squibb continues to underperform Novartis by 18.8% year to date

  Fuster, V.

  20/05/25

  5 items of Media coverage

  Press/Media

• Tourmaline Bio Announces Positive Topline Results From The Ongoing Phase 2 TRANQUILITY Trial Evaluating Pacibekitug In Patients With Elevated High-Sensitivity C-Reactive Protein And Chronic Kidney Disease

  Fuster, V. & Bhatt, D. L.

  20/05/25

  7 items of Media coverage

  Press/Media

• Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025

  Fuster, V. & Bhatt, D. L.

  20/05/25

  1 item of Media coverage

  Press/Media

• Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025

  Fuster, V. & Bhatt, D. L.

  20/05/25

  2 items of Media coverage

  Press/Media

• To Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025

  Fuster, V. & Bhatt, D. L.

  20/05/25

  1 item of Media coverage

  Press/Media

• Tourmaline Bio Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

  Fuster, V. & Bhatt, D. L.

  20/05/25

  1 item of Media coverage

  Press/Media